KRAS and neoplasm: Of note, the only RASGRF fusion we identified in a PDAC with a concurrent KRAS mutation is MSH3-RASGRF2 (which lacks the PH1 but not DH domain), suggesting the fusion is unlikely to be an oncogenic driver in that tumor (Supplementary Fig. 2).